Table S1: Survey Data- Comparison by region

		Total	Comparison by Region*						
Question	Categories		Aus/NZ	Europe	Latin America	North America	Other	p value	
		(N=175)	(N=13)	(N=40)	(N=12)	(N=97)	(N=13)		
Did your center use low-dose acyclovir in allogeneic transplant	No	33 (18.9%)	4 (30.8%)	11 (27.5%)	1 (8.3%)	11 (11.3%)	6 (46.2%)	0.006	
recipients who were VZV+ or HSV+?	Yes	142 (81.1%)	9 (69.2%)	29 (72.5%)	11 (91.7%)	86 (88.7%)	7 (53.8%)		
					, , , , ,				
Indicate the low-dose acyclovir prophylactic treatment strategy	Do not Treat	34 (23.9%)	3 (33.3%)	3 (10.3%)	3 (27.3%)	25 (29.1%)	0 (0.0%)	0.008	
used in VZV+ patients	Other duration	30 (21.1%)	1 (11.1%)	6 (20.7%)	0 (0.0%)	21 (24.4%)	2 (28.6%)		
	Treat for 12 months	27 (19.0%)	1 (11.1%)	0	2 (18.2%)	24 (27.9%)	0 (0.0%)		
	Treat for 3 to 4 months	33 (23.2%)	2 (22.2%)	13 (44.8%)	3 (27.3%)	11 (12.8%)	4 (57.1%)		
	Treat until engraftment	18 (12.7%)	2 (22.2%)	7	3 (27.3%)	5 (5.8%)	1 (14.3%)		
				1	1		1		
Indicate the low-dose acyclovir prophylactic treatment strategy	Do not Treat	2 (1.4%)	0 (0.0%)	0 (0.0%)	1 (9.1%)	1 (1.2%)	0 (0.0%)	0.017**	
used in HSV+ patients- (VZV -)	Other duration	34 (23.9%)	1 (11.1%)	6 (20.7%)	0 (0.0%)	26 (30.2%)	1 (14.3%)		
	Treat for 12 months	24 (16.9%)	1 (11.1%)	0 (.%)	2 (18.2%)	21 (24.4%)	0 (.%)		
	Treat for 3 to 4 months	44 (31.0%)	3 (33.3%)	13 (44.8%)	4 (36.4%)	20 (23.3%)	4 (57.1%)		
	Treat until engraftment	38 (26.8%)	4 (44.4%)	10 (34.5%)	4 (36.4%)	18 (20.9%)	2 (28.6%)		
		, , , , , , ,		((/	/		
Did your center use prophylactic high-dose acyclovir in allogeneic	No	120 (68.6%)	8 (61.5%)	21 (52.5%)	7 (58.3%)	74 (76.3%)	10 (76.9%)	0.063	

transplant recipients who were CMV+?	Yes	55 (31.4%)	5 (38.5%)	19 (47.5%)	5 (41.7%)	23 (23.7%)	3 (23.1%)	
Indicate the prophylactic high- dose acyclovir treatment	Other duration	10 (18.2%)	1 (20.0%)	3 (15.8%)	0 (.%)	5 (22.7%)	1 (25.0%)	0.005
strategy used in CMV + transplant recipients	Treat for 12 months	7 (12.7%)	0 (.%)	0 (.%)	0 (.%)	6 (27.3%)	1 (25.0%)	
	Treat for 3 to 4 months	22 (40.0%)	4 (80.0%)	11 (57.9%)	4 (80.0%)	2 (9.1%)	1 (25.0%)	
	Treat until engraftment	16 (29.1%)	0 (.%)	5 (26.3%)	1 (20.0%)	9 (40.9%)	1 (25.0%)	
Did your center use a strategy of routine ganciclovir prophylaxis in	No	126 (72.4%)	6 (46.2%)	30 (75.0%)	8 (66.7%)	75 (78.1%)	7 (53.8%)	0.069
some transplant recipients?	Yes	48 (27.6%)	7 (53.8%)	10 (25.0%)	4 (33.3%)	21 (21.9%)	6 (46.2%)	
				-	•	•	•	
When was prophylaxis initiated?	At time of engraftment	26 (53.1%)	2 (28.6%)	7 (70.0%)	2 (50.0%)	13 (61.9%)	2 (28.6%)	0.446
	Other initiation schedule	10 (20.4%)	2 (28.6%)	1 (10.0%)	0 (.%)	4 (19.0%)	3 (42.9%)	
	Pre-transplantation	13 (26.5%)	3 (42.9%)	2	2 (50.0%)	4 (19.0%)	2 (28.6%)	
What was the duration of ganciclovir prophylaxis?	Greater than 3 months but less than or equal to 6	8 (16.3%)	1 (14.3%)	1 (10.0%)	1 (25.0%)	4 (19.0%)	1 (14.3%)	0.735
	Less than or equal to 3 months	36 (73.5%)	6 (85.7%)	9 (90.0%)	3 (75.0%)	14 (66.7%)	4 (57.1%)	
	Other duration	5 (10.2%)	0 (.%)	0 (.%)	0 (.%)	3 (14.3%)	2 (28.6%)	
						•		
Did your center use a strategy of surveillance and preemptive	No	16 (9.2%)	4 (30.8%)	2 (5.0%)	2 (16.7%)	5 (5.2%)	3 (23.1%)	0.007
therapy in at least some transplant recipients?	Yes	158 (90.8%)	9 (69.2%)	38 (95.0%)	10 (83.3%)	91 (94.8%)	10 (76.9%)	
		` '		/		, ,	/	

Please indicate the primary	ON () (() (O5)	72	3	16	0 (00 00()	40	7	0.705
means of surveillance used.	CMV antigenemia (pp65)	(45.3%)	(33.3%)	(42.1%)	6 (60.0%)	(44.0%)	(63.6%)	0.725
	Other method	7	0	2	0	4	1	
	Other method	(4.4%)	(.%)	(5.3%)	(.%)	(4.4%)	(9.1%)	
	Plasma CMV-DNA PCR	45	3	8	2 (20.0%)	30	2	
		(28.3%)	(33.3%)		_ (_0.070)	(33.0%)	(18.2%)	
	Whole blood or leukocyte	35	3	12	2 (20.0%)	17	1 (0.40()	
	CMV-DNA PCR	(22.0%)	(33.3%)	(31.6%)	` ′	(18.7%)	(9.1%)	
Which transplant recipients	All recipients regardless of	98	5	31		46	7	
underwent routine surveillance?	CMV serologic status	(61.6%)	(55.6%)		9 (90.0%)	(50.5%)	(63.6%)	<.001
underwent routine surveillance:	CMV seropositive recipients	57	4	5		44	3	
	(D+/R+ and D-/R+)	(35.8%)	(44.4%)	_	1 (10.0%)	(48.4%)	(27.3%)	
	Only CMV seropositive	3	0	2	0	1	0	
	recipients (D+/R+ and D-/R+)	(1.9%)	(.%)	(5.3%)	(0.0%)	(1.1%)	(.%)	
	Other surveillance strategy	1	0	0	0	0	1	
	Other surveillance strategy	(0.6%)	(.%)	(.%)	(.%)	(.%)	(9.1%)	
				7	•			
How often were surveillance	Other routine	8 (5.0%)	0	4	0	2	2	0.158
studies administered in the first		0 (0.070)	(.%)	(10.5%)	(.%)	(2.2%)	(18.2%)	
10 days post-transplant?	Twice per month	8 (5.0%)	0 (.%)	1 (2.6%)	1 (10.0%)	5 (5.5%)	1 (9.1%)	
		143	9	33		84	8	
	Weekly or more frequently	(89.9%)	(100%)	(86.8%)	9 (90.0%)	(92.3%)	(72.7%)	
		(/	(/	(/		()	,	
If CMV was detected by	2.2 weeks	14	0	2	4 (40 00()	10	1	0.502
surveillance, how long were	2-3 weeks	14 (8.9%)	0 (.%)	2 (5.3%)	1 (10.0%)	10 (11.0%)	1 (10.0%)	0.593
	2-3 weeks 2-3 weeks, or until clearance				` ′			0.593
surveillance, how long were		(8.9%) 90 (57.0%)	(.%) 7 (77.8%)	(5.3%) 25 (65.8%)	8 (80.0%)	(11.0%) 44 (48.4%)	(10.0%) 6 (60.0%)	0.593
surveillance, how long were	2-3 weeks, or until clearance of CMV antigen or DNA	(8.9%) 90 (57.0%) 12	(.%) 7 (77.8%) 0	(5.3%) 25 (65.8%) 1	8 (80.0%)	(11.0%) 44 (48.4%) 10	(10.0%) 6 (60.0%) 1	0.593
surveillance, how long were	2-3 weeks, or until clearance of CMV antigen or DNA Other length of treatment	(8.9%) 90 (57.0%) 12 (7.6%)	(.%) 7 (77.8%) 0 (.%)	(5.3%) 25 (65.8%) 1 (2.6%)	8 (80.0%) 0 (.%)	(11.0%) 44 (48.4%) 10 (11.0%)	(10.0%) 6 (60.0%) 1 (10.0%)	0.593
surveillance, how long were	2-3 weeks, or until clearance of CMV antigen or DNA Other length of treatment Until clearance of CMV	(8.9%) 90 (57.0%) 12 (7.6%) 25	(.%) 7 (77.8%) 0 (.%) 2	(5.3%) 25 (65.8%) 1 (2.6%) 8	8 (80.0%) 0 (.%)	(11.0%) 44 (48.4%) 10 (11.0%)	(10.0%) 6 (60.0%) 1 (10.0%) 2	0.593
surveillance, how long were	2-3 weeks, or until clearance of CMV antigen or DNA Other length of treatment	(8.9%) 90 (57.0%) 12 (7.6%) 25 (15.8%)	(.%) 7 (77.8%) 0 (.%) 2 (22.2%)	(5.3%) 25 (65.8%) 1 (2.6%) 8 (21.1%)	8 (80.0%) 0 (.%)	(11.0%) 44 (48.4%) 10 (11.0%) 13 (14.3%)	(10.0%) 6 (60.0%) 1 (10.0%) 2 (20.0%)	0.593
surveillance, how long were	2-3 weeks, or until clearance of CMV antigen or DNA Other length of treatment Until clearance of CMV	(8.9%) 90 (57.0%) 12 (7.6%) 25 (15.8%) 17	(.%) 7 (77.8%) 0 (.%) 2 (22.2%)	(5.3%) 25 (65.8%) 1 (2.6%) 8 (21.1%)	8 (80.0%) 0 (.%)	(11.0%) 44 (48.4%) 10 (11.0%) 13 (14.3%)	(10.0%) 6 (60.0%) 1 (10.0%) 2 (20.0%) 0	0.593
surveillance, how long were	2-3 weeks, or until clearance of CMV antigen or DNA Other length of treatment Until clearance of CMV antigen or DNA	(8.9%) 90 (57.0%) 12 (7.6%) 25 (15.8%)	(.%) 7 (77.8%) 0 (.%) 2 (22.2%)	(5.3%) 25 (65.8%) 1 (2.6%) 8 (21.1%)	8 (80.0%) 0 (.%) 0 (.%)	(11.0%) 44 (48.4%) 10 (11.0%) 13 (14.3%)	(10.0%) 6 (60.0%) 1 (10.0%) 2 (20.0%)	0.593

Did your center use a prophylactic or preemptive	No	52 (29.9%)	3 (23.1%)	8 (20.0%)	4 (33.3%)	31 (32.3%)	6 (46.2%)	0.385
approach to CMV in high-risk transplant recipients after day	Yes	122 (70.1%)	10 (76.9%)	32 (80.0%)	8 (66.7%)	65 (67.7%)	7 (53.8%)	
Inidicate the primary strategy	Antiviral prophylaxis with high-	4	1	1	0	2	0	0.611
used in high-risk recipients after	dose valacyclovir	(3.3%)	(10.0%)	` ,	(.%)	(3.1%)	(.%)	0.011
day 100.	Antiviral prophylaxis with oral	2	0	0	0	1	1	
	valgancyclovir	(1.6%)	(.%)	(.%)	(.%)	(1.5%)	(14.3%)	
	Other strategy	6 (4.9%)	0 (.%)	0 (.%)	0 (.%)	6 (9.2%)	0 (.%)	
	Treatment of disease	14 (11.5%)	1 (10.0%)	4 (12.5%)	0 (.%)	8 (12.3%)	1 (14.3%)	
	Virologic surveillance/	96	8	27	8	48	5	
	preemptive therapy	(78.7%)	(80.0%)	(84.4%)	(100%)	(73.8%)	(71.4%)	
16 11 6						- 40		
If surveillance was used after day 100, how often were	Other routine	22 (18.8%)	1 (10.0%)	6 (18.8%)	0 (.%)	13 (21.3%)	2 (33.3%)	0.706
surveillance tests administered?	Twice per month	61 (52.1%)	5 (50.0%)	17 (53.1%)	5 (62.5%)	30 (49.2%)	4 (66.7%)	
	Weekly or more frequently	34 (29.1%)	4 (40.0%)	9 (28.1%)	3 (37.5%)	18 (29.5%)	0 (.%)	
							, ,	
Did your center have a strategy for using CMV seronegative	No	12 (6.9%)	0 (.%)	2 (5.0%)	0 (.%)	6 (6.3%)	4 (30.8%)	0.045
blood products and/or leukoreduction in allogeneic	Yes	162 (93.1%)	13 (100%)	38 (95.0%)	12 (100%)	90 (93.8%)	9 (69.2%)	
		,	,	,	//	,	,	
Indicate your center's primary strategy.	Both CMV seronegative blood products and leukoreduction	60 (37.0%)	2 (15.4%)	16 (42.1%)	2 (16.7%)	38 (42.2%)	2 (22.2%)	0.097
	CMV seronegative blood	10	3	1	0	6	0	
	products ONLY	(6.2%)	(23.1%)	(2.6%)	(.%)	(6.7%)	(.%)	
	Either, CMV seronegative	34	7	5	1	18	3	
	blood products preferred	(21.0%)	(53.8%)	(13.2%)	(8.3%)	(20.0%)	(33.3%)	
	Either, no preference	4 (2.5%)	0 (.%)	0 (.%)	1 (8.3%)	3 (3.3%)	0 (.%)	

		40	1	4.4	I	00	3	
	Leukoreduction ONLY	48 (29.6%)	(7.7%)	14 (36.8%)	8 (66.7%)	22 (24.4%)	(33.3%)	
		6	0	2	0	3	1	
	Other Strategy	(3.7%)	(.%)	(5.3%)	(.%)	(3.3%)	(11.1%)	
		, ,				<u> </u>		
Indicate which patients received	All potionto	76	3	21	7 (50 20/)	40	5	0.071
CMV-seronegative blood	All patients	(46.9%)	(23.1%)	(55.3%)	7 (58.3%)	(44.4%)	(55.6%)	0.071
products and/or leukoreductions.	Only CMV D-/R-	39	5	12	1	18	3	
	Offiny ONLY 15 /TK	(24.1%)	(38.5%)	(31.6%)	(8.3%)	(20.0%)	(33.3%)	
	Other patient groups	6	0	1	0	4	1	
	Guier patient groups	(3.7%)	(.%)	(2.6%)	(.%)	(4.4%)	(11.1%)	
	CMV D-/R- and D+/R-	41	5	4	4 (33.3%)	28	0	
		(25.3%)	(38.5%)	(10.5%)	. (66.676)	(31.1%)	(.%)	
				1				
Did your center ever use	No	167	13	38	12	92	12	0.9
adoptive immunotherapy in		(96.0%)	(100%)	(95.0%)	(100%)	(95.8%)	(92.3%)	
allogeneic transplant recipients?	Yes	7	0	2	0	4	1 (7.70()	
		(4.0%)	(.%)	(5.0%)	(.%)	(4.2%)	(7.7%)	
Indicate vour contario primari	Only often failure of museumative	4	0	1	_	Ī	1 4	
Indicate your center's primary strategy for using adoptive	Only after failure of preemptive	(57.1%)	0 (.%)	(50.0%)	0 (.%)	2 (50.0%)	(100%)	1
immunotherapy.	therapy	2	0	1	0		0	
illillidilotilerapy.	Used as preemptive therapy	(28.6%)	(.%)	(50.0%)	(.%)	1 (25.0%)	(.%)	
		1	0	0	0		, O	
	Used as prophylaxis	(14.3%)	(.%)	(.%)	(.%)	1 (25.0%)	(.%)	
		(1.11070)	(1,70)	(1,70)	(1,70)	<u>l</u>	(1,70)	
Did your center use systemic		19	0	9	0	6	4	0.005
antifungal prophylaxis in	No	(10.9%)	(.%)	(22.5%)	(.%)	(6.3%)	(30.8%)	0.005
allogeneic transplant recipients?	Vac	155	13	31	12	90	9	
	Yes	(89.1%)	(100%)	(77.5%)	(100%)	(93.8%)	(69.2%)	
Indicate when your center	With conditioning regimen	97	9	25	9 (75.0%)	49	5	0.007
initiated antifungal prophylaxis.	<u> </u>	(62.6%)	(69.2%)	(80.7%)	3 (73.070)	(54.4%)	(55.6%)	0.007
	At infusion of graft	42	4	1	2 (16.7%)	33	2	
	(Day 0 +/- 1 day)	(27.1%)	(30.8%)	(3.2%)	2 (10.770)	(36.7%)	(22.2%)	

	Other	16 (10.3%)	0 (.%)	5 (16.1%)	1 (8.3%)	8 (8.9%)	2 (22.2%)	
			,		, ,	,	, , ,	
Indicate the duration of antifungal prophylaxis used by	Treat until engraftment	35 (22.7%)	3 (23.1%)	8 (25.8%)	3 (25.0%)	15 (16.9%)	6 (66.7%)	0.116
your center.	Treat until day 75-100	74 (48.1%)	8 (61.5%)	16 (51.6%)	6 (75.0%)	42 (47.2%)	2 (22.2%)	
	Other	45 (29.2%)	2 (15.3%)	7 (22.6%)	3 (25.0%)	32 (36.0%)	1 (11.1%)	
Indicate the primary drug used for systemic antifungal	Fluconazole	124 (80.5%)	11 (84.6%)	21 (67.7%)	12 (100%)	73 (82.2%)	7 (77.8%)	0.098
prophylaxis at your center.	Itraconazole	18 (11.69%	1 (7.7%)	9 (29.3%)	0 (.%)	7 (7.9%)	1 (11.1%)	
	Other	12 (7.8%)	1 (7.7%)	1 (3.2%)	0 (.%)	9 (10.1%)	1 (11.1%)	

^{*} Countries represented by region (number of responding programs): US/Can--United States (90), Canada (7); Europe--Germany (13)United Kingdom (7), Spain (5), Belgium (3), Sweden (2), Finland (2), Italy (2), Switzerland (1), Norway (1), Denmark (1), Poland (1), Portugal (1), Czech Republic (1); Australia/NZ-- Australia (10), New Zealand (3); Latin America-- Brazil (3), Argentina (3), Uruguay (3), Venezuela (2), Mexico (1); Middle East-- Israel (2), Iran (1), Pakistan (1); Asia-- India (2), China, Hong Kong (1), Japan (1), Taiwan (1), Korea (1); Africa-- South Africa (3)

^{**}P value for comparison only between those regions that treated until engraftment, 3-4 months, and 12 months only.

Table S2: Survey data- Comparison by patient population and center size

	, , , ,	Patient F	opulation	n		Center Size			
Question	Categories	Both adult and pediatri c patients (N=57)	Adult patients only	Pediatric patients only (N=37)	p value	≤ 50 annual trans- plants (N=108)	> 50 annual trans- plants (N=56)	p value	
Did your center use low-dose acyclovir in allogeneic transplant	No	11 (19.3%)	15 (18.5%)	7 (18.9%)	1	16 (14.8%)	14 (25.0%)	0.11	
recipients who were VZV+ or HSV+?	Yes	46 (80.7%)	66 (81.5%)	30 (81.1%)		92 (85.2%)	42 (75.0%)		
Indicate the low-dose acyclovir prophylactic treatment strategy	Do not Treat	14 (30.4%)	12 (18.2%)	8 (26.7%)	0.727	25 (27.2%)	7 (16.7%)	0.534	
used in VZV+ patients	Other duration	7 (15.2%)	17 (25.8%)	6 (20.0%)		16 (17.4%)	10 (23.8%)		
	Treat for 12 months	8 (17.4%)	14 (21.2%)	5 (16.7%)		19 (20.7%)	8 (19.0%)		
	Treat for 3 to 4 months	13 (28.3%)	13 (19.7%)	7 (23.3%)		23 (25.0%)	10 (23.8%)		
	Treat until engraftment	4 (8.7%)	10 (15.2%)	4 (13.3%)		9 (9.8%)	7 (16.7%)		
Indicate the low-dose acyclovir prophylactic treatment strategy	Do not Treat	0 (.%)	1 (1.5%)	1 (3.3%)	0.839	2 (2.2%)	0 (.%)	0.688	
used in HSV+ patients- (VZV -)	Other duration	10 (21.7%)	17 (25.8%)	7 (23.3%)		20 (21.7%)	10 (23.8%)		
	Treat for 12 months	7 (15.2%)	14 (21.2%)	3 (10.0%)		16 (17.4%)	7 (16.7%)		
	Treat for 3 to 4 months	15 (32.6%)	18 (27.3%)	11 (36.7%)		32 (34.8%)	11 (26.2%)		

	Treat until engraftment	14 (30.4%)	16 (24.2%)	8 (26.7%)		22 (23.9%)	14 (33.3%)	
Did your center use prophylactic high-dose acyclovir in allogeneic	No	40 (70.2%)	63 (77.8%)	17 (45.9%)	0.002	73 (67.6%)	38 (67.9%)	0.973
transplant recipients who were CMV+?	Yes	17 (29.8%)	18 (22.2%)	20 (54.1%)		35 (32.4%)	18 (32.1%)	
Indicate the prophylactic high- dose acyclovir treatment	Other duration	2 (11.1%)	4 (23.5%)	4 (20.0%)	0.746	6 (16.7%)	4 (22.2%)	0.098
strategy used in CMV + transplant recipients	Treat for 12 months	2 (11.1%)	2 (11.8%)	3 (15.0%)		2 (5.6%)	5 (27.8%)	
	Treat for 3 to 4 months	6 (33.3%)	8 (47.1%)	8 (40.0%)		15 (41.7%)	6 (33.3%)	
	Treat until engraftment	8 (44.4%)	3 (17.6%)	5 (25.0%)		13 (36.1%)	3 (16.7%)	
Did your center use a strategy of routine ganciclovir prophylaxis in	No	39 (68.4%)	57 (71.3%)	30 (81.1%)	0.393	81 (75.0%)	39 (69.6%)	0.463
some transplant recipients?	Yes	18 (31.6%)	23 (28.8%)	7 (18.9%)		27 (25.0%)	17 (30.4%)	
When was prophylaxis initiated?	At time of engraftment	11 (57.9%)	12 (52.2%)	3 (42.9%)	0.854	15 (53.6%)	9 (52.9%)	0.921
	Other initiation schedule	4 (21.1%)	5 (21.7%)	1 (14.3%)		5 (17.9%)	4 (23.5%)	
	Pre-transplantation	4 (21.1%)	6 (26.1%)	3 (42.9%)		8 (28.6%)	4 (23.5%)	
What was the duration of ganciclovir prophylaxis?	Greater than 3 months but less than or equal to 6	3 (15.8%)	` '	1 (14.3%)	0.758	6 (21.4%)	2 (11.8%)	0.885
	Less than or equal to 3 months	13 (68.4%)	18 (78.3%)	5 (71.4%)		19 (67.9%)	13 (76.5%)	
	Other duration	3 (15.8%)	1 (4.3%)	1 (14.3%)		3 (10.7%)	2 (11.8%)	

Did your center use a strategy of surveillance and preemptive	No	5 (8.8%)	7 (8.8%)	4 (10.8%)	0.889	12 (11.1%)	3 (5.4%)	0.268
therapy in at least some transplant recipients?	Yes	52 (91.2%)	73 (91.3%)	33 (89.2%)		96 (88.9%)	53 (94.6%)	
		((= = =)	(=====		(====)	(= = = =)	
Please indicate the primary means of surveillance used.	CMV antigenemia (pp65)	27 (50.9%)	30 (41.1%)	15 (45.5%)	0.544	44 (45.4%)	23 (43.4%)	0.97
	Other method	2 (3.8%)	4 (5.5%)	1 (3.0%)		4 (4.1%)	3 (5.7%)	
	Plasma CMV-DNA PCR	12 (22.6%)	20 (27.4%)	13 (39.4%)		27 (27.8%)	15 (28.3%)	
	Whole blood or leukocyte CMV-DNA PCR	12 (22.6%)	19 (26.0%)	4 (12.1%)		22 (22.7%)	12 (22.6%)	
		(==:070)	(=0.070)	(121170)		(==:: /5/	(==:070)	
Which transplant recipients underwent routine surveillance?	All recipients regardless of CMV serologic status	34 (64.2%)	41 (56.2%)	23 (69.7%)	0.649	56 (57.7%)	38 (71.7%)	0.104
	CMV seropositive recipients (D+/R+ and D-/R+)	17 (32.1%)	30 (41.1%)	10 (30.3%)		39 (40.2%)	13 (24.5%)	
	Only CMV seropositive recipients (D+/R+ and D-/R+)	1 (1.9%)	2 (2.7%)	0 (.%)		1 (1.0%)	2 (3.8%)	
	Other surveillance strategy	1 (1.9%)	0 (0.0%)	0 (.%)		1 (1.0%)	0 (.%)	
How often were surveillance studies administered in the first	Other routine	2 (3.8%)	4 (5.5%)	2 (6.1%)	0.945	5 (5.2%)	2 (3.8%)	0.834
10 days post-transplant?	Twice per month	3 (5.7%)	3 (4.1%)	2 (6.1%)		6 (6.2%)	2 (3.8%)	
	Weekly or more frequently	48 (90.6%)	66 (90.4%)	29 (87.9%)		86 (88.7%)	49 (92.5%)	
If CMV was detected by surveillance, how long were	2-3 weeks	4 (7.7%)	8 (11.0%)	2 (6.1%)	0.84	5 (5.2%)	9 (17.0%)	0.117
patients usually treated?	2-3 weeks, or until clearance of CMV antigen or DNA	26 (50.0%)	45 (61.6%)	19 (57.6%)		59 (61.5%)	25 (47.2%)	
	Other length of treatment	6 (11.5%)	4 (5.5%)	2 (6.1%)		6 (6.3%)	6 (11.3%)	

	Until clearance of CMV antigen or DNA	10 (19.2%)	9 (12.3%)	6 (18.2%)		15 (15.6%)	8 (15.1%)	
	Until day 100 after transplant	6 (11.5%)	7 (9.6%)	4 (12.1%)		11 (11.5%)	5 (9.4%)	
Did your center use a prophylactic or preemptive	No	22 (38.6%)	19 (23.8%)	11 (29.7%)	0.174	30 (27.8%)	17 (30.4%)	0.729
approach to CMV in high-risk transplant recipients after day	Yes	35 (61.4%)	61 (76.3%)	26 (70.3%)		78 (72.2%)	39 (69.6%)	
Inidicate the primary strategy used in high-risk recipients after	Antiviral prophylaxis with high-dose valacyclovir	1 (2.9%)	3 (4.9%)	0 (.%)	0.921	3 (3.8%)	1 (2.6%)	0.07
day 100.	Antiviral prophylaxis with oral valgancyclovir	0 (.%)	1 (1.6%)	1 (3.8%)		2 (2.6%)	0 (.%)	
	Other strategy	1 (2.9%)	4 (6.6%)	1 (3.8%)		2 (2.6%)	3 (7.7%)	
	Treatment of disease	3 (8.6%)	8 (13.1%)	3 (11.5%)		13 (16.7%)	1 (2.6%)	
	Virologic surveillance/ preemptive therapy	30 (85.7%)	45 (73.8%)	21 (80.8%)		58 (74.4%)	34 (87.2%)	
If surveillance was used after day 100, how often were	Other routine	5 (14.7%)	13 (22.0%)	4 (16.7%)	0.539	15 (20.3%)	7 (18.4%)	0.897
surveillance tests administered?	Twice per month	17 (50.0%)	33 (55.9%)	11 (45.8%)		37 (50.0%)	21 (55.3%)	
	Weekly or more frequently	12 (35.3%)	13 (22.0%)	9 (37.5%)		22 (29.7%)	10 (26.3%)	
Did your center have a strategy for using CMV seronegative	No	8 (14.0%)	2 (2.5%)	2 (5.4%)	0.035	7 (6.5%)	5 (8.9%)	0.546
blood products and/or leukoreduction in allogeneic	Yes	49 (86.0%)	78 (97.5%)	35 (94.6%)		101 (93.5%)	51 (91.1%)	
Indicate your center's primary strategy.	Both CMV seronegative blood products and leukoreduction	14 (28.6%)	36 (46.2%)	10 (28.6%)	0.016	35 (34.7%)	22 (43.1%)	0.659

antifungal prophylaxis in allogeneic transplant recipients? 10.5% (10.5%) (15.0%) (2.7%) 0.129 (8.3%) (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.	1	losni i i i i				ı			i
Either, CMV seronegative blood products preferred (26.5%) (16.7%) (22.9%) (22.9%) (20.8%) (19.6%) (19.6%) (19.6%) (20.8%) (19.6%) (20.8%) (19.6%) (20.8%) (19.6%) (20.8%) (19.6%) (20.8%) (19.6%) (20.8%) (20.9%) (20.8%) (20.9%) (20.8%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.9%) (20.			_	=					
Blood products preferred (26.5%) (16.7%) (22.9%) (20.8%) (19.6%)		-		` ,	`		` ,	`	
Either, no preference				_	_			_	
Either, no preference Leukoreduction ONLY Leuk		blood products preferred	(26.5%)	(16.7%)	(22.9%)		(20.8%)	(19.6%)	
Leukoreduction ONLY 19 17 12 33 13 (32.7%) (25.5%)		Lither ne preference	0	2	2		3	1	
Leukoreduction ONLY (38.8%) (21.8%) (34.3%) (32.7%) (25.5%) (5.9%) (6.1%) (38.8%) (21.8%) (34.3%) (32.7%) (25.5%) (5.9%) (6.1%) (6.1%) (38.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8%) (.8		Either, no preference	(.%)	(2.6%)	(5.7%)		(3.0%)	(2.0%)	
Other Strategy Other Strategy		La Landaga ONIV	19	17	12		33	13	
Indicate which patients received CMV-seronegative blood products and/or leukoreductions.		Leukoreduction ONLY	(38.8%)	(21.8%)	(34.3%)		(32.7%)	(25.5%)	
Indicate which patients received CMV-seronegative blood products and/or leukoreductions. All patients 26 28 22 0.068 46 26 (45.5%) (51.0%) Only CMV D-/R- (18.4%) (30.8%) (17.1%) Other patient groups 0 5 1 4 2 (4.0%) (3.9%) CMV D-/R- and D+/R- (28.6%) (26.9%) (17.1%) Did your center ever use adoptive immunotherapy in allogeneic transplant recipients? No 5 (93.0%) (98.8%) (94.6%) (1.3%) (5.4%) Indicate your center's primary strategy for using adoptive immunotherapy. Did your center ever use approphylaxis in allogeneic transplant recipients? No 6 1 2 1 0 0 0 0 0 1 (33.3%) Used as prophylaxis No 6 1 2 1 0 0.129 9 10 (17.9%) No (10.5%) (15.0%) (2.7%) (19.9%) Only after failure of preemptive therapy (75.0%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.		Other Others	3	3	0		2	3	
All patients received CMV-seronegative blood products and/or leukoreductions.		Other Strategy	(6.1%)	(3.8%)	(.%)		(2.0%)	(5.9%)	
CMV-seronegative blood products and/or leukoreductions. All patients (53.1%) (35.9%) (62.9%) (0.068 (45.5%) (51.0%) (0.739 (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (1									
CMV-seronegative blood products and/or leukoreductions. All patients (53.1%) (35.9%) (62.9%) (0.068 (45.5%) (51.0%) (0.739 (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (10.0%) (1	Indicate which patients received		26	28	22		46	26	
Only CMV D-/R- 9 24 6 (23 13 (22.8%) (25.5%) (25.5%) (25.5%) (22.8%) (25.5%) (25.5%) (22.8%) (25.5%) (25.5%) (22.8%) (25.5%) (22.8%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25.5%) (25	•	All patients				0.068			0.739
Contemplate	•							,	
Other patient groups		Only CMV D-/R-			_				
Other patient groups (.%) (6.4%) (2.9%) (4.0%) (3.9%) CMV D-/R- and D+/R- 14			, ,	,	` ,		,	` ,	
CMV D-/R- and D+/R-		Other patient groups	_	_	-				
CMV D-/R- and D+/R- (28.6%) (26.9%) (17.1%) (27.7%) (19.6%)			\ /	,	` ,			. ,	
Did your center ever use adoptive immunotherapy in allogeneic transplant recipients? No Signature (93.0%) Yes No Signature (93.0%) Yes No Signature (93.0%) Yes Signature (93.0%) Yes Signature (93.0%) Yes Signature (93.0%) Yes Signature (93.0%) Signature (94.6%) Yes Signature (93.0%) Signature (94.6%) Signature (94		CMV D-/R- and D+/R-			_				
No (93.0%) (98.8%) (94.6%) (07.2%) (94.6%) (07.2%) (94.6%) (07.2%) (94.6%) (07.2%) (94.6%) (07.2%) (94.6%) (07.2%) (94.6%) (07.2%) (94.6%) (07.2%) (94.6%) (07.2%) (94.6%) (07.2%) (94.6%) (07.2%) (94.6%) (07.2%) (97.2%) (94.6%) (07.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2%) (97.2			(20.070)	(20.570)	(17.170)		(21.170)	(13.070)	
No (93.0%) (98.8%) (94.6%) (0.197 (97.2%) (94.6%) (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412 (0.412	Did your contor over use		F2	70	25		105	52	
Allogeneic transplant recipients? Yes 4 1 2 3 (2.8%) (5.4%) Indicate your center's primary strategy for using adoptive immunotherapy. Only after failure of preemptive therapy Used as preemptive therapy Used as prophylaxis Olid your center use systemic antifungal prophylaxis in allogeneic transplant recipients? Yes 4 1 2 3 (2.8%) (5.4%) (7.0%) (1.3%) (5.4%) 0 1 0.429 (66.7%) (33.3%) 1 1 (100.0%) (50.0%) (100.0%) (50.0%) (100.0%) (50.0%) (100.0%) (50.0%) (100.0%) (50.0%) (100.0%) (50.0%) (100.0%) (50.0%) (100.0%) (50.0%) (100.0%) (50.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (No		_		0.197			0.412
Yes (7.0%) (1.3%) (5.4%) (2.8%) (5.4%)			, ,	,	,		,	` ′	
Indicate your center's primary strategy for using adoptive immunotherapy. Only after failure of preemptive therapy Used as prophylaxis Oliv after failure of preemptive therapy Used as prophylaxis Only after failure of preemptive therapy (75.0%) (.%) (50.0%) (.%) (66.7%) (33.3%) (33.3%) Used as prophylaxis Only after failure of preemptive therapy (75.0%) (.%) (50.0%) (.%) (50.0%) Onder the preemptive therapy Used as prophylaxis Only after failure of preemptive therapy (75.0%) (.%) (50.0%) (.%) (33.3%) (33.3%) Onder the preemptive therapy Only after failure of preemptive therapy (75.0%) (.%) (50.0%) (.%) (33.3%) (33.3%) Onder the preemptive therapy Used as prophylaxis Only after failure of preemptive therapy Only after failure of (.%) (50.0%) (.%) (50.0%) Onder the preemptive therapy Only after failure of (.%) (50.0%) (.%) (50.0%) Onder the preemptive therapy Onder the pr	allogeneic transplant recipients?	Yes	·-	•	_		_	-	
strategy for using adoptive immunotherapy. Did your center use systemic antifungal prophylaxis in allogeneic transplant recipients? Did your center use systemic antigungal prophylaxis Did your center use systemic allogeneic transplant recipients? Did your center use systemic allogeneic transplant recipients Did your center use systemic allogeneic transplant recipients Did your center use systemic allogene			(7.0%)	(1.3%)	(5.4%)		(2.8%)	(5.4%)	
strategy for using adoptive immunotherapy. Did your center use systemic antifungal prophylaxis in allogeneic transplant recipients? Did your center use systemic antigungal prophylaxis Did your center use systemic allogeneic transplant recipients? Did your center use systemic allogeneic transplant recipients Did your center use systemic allogeneic transplant recipients Did your center use systemic allogene	In Proceedings of the Control				4			4	
Used as preemptive therapy				_		0.429		-	1
Used as preemptive therapy (.%) (100.0% (50.0%) (33.3%) (33.3%) (33.3%)	· ·	preemptive therapy	,	` ,	(50.0%)		,	` ,	
Used as prophylaxis 1 0 0 0 (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%)	immunotherapy.	Used as preemptive therapy	_	•	1			•	
Used as prophylaxis (25.0%) (.%) (.%) (.%) (.%) (33.3%)			` ′	`	` ,		·	(33.3%)	
Did your center use systemic antifungal prophylaxis in allogeneic transplant recipients? (25.0%)		Used as prophylaxis		Ŭ	Ŭ			1	
antifungal prophylaxis in allogeneic transplant recipients? No (10.5%) (15.0%) (2.7%) 0.129 (8.3%) (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.0		Cood do propriyidado	(25.0%)	(.%)	(.%)		(.%)	(33.3%)	
antifungal prophylaxis in allogeneic transplant recipients? No (10.5%) (15.0%) (2.7%) 0.129 (8.3%) (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.078 (17.9%) 0.0									
antifungal prophylaxis in (10.5%) (15.0%) (2.7%) (8.3%) (17.9%) allogeneic transplant recipients?	Did your center use systemic	No	6		•	0.120	9	10	0.078
	antifungal prophylaxis in	INO	(10.5%)	(15.0%)	(2.7%)	0.129	(8.3%)	(17.9%)	0.076
1 res (89.5% (85.0%) (97.3%) (91.7%) (82.1%)	allogeneic transplant recipients?	Vac	51	68	36		99	46	
[(01.170) [(02.170) [res	(89.5%	(85.0%)	(97.3%)		(91.7%)	(82.1%)	

Indicate when your center initiated antifungal prophylaxis.	With conditioning regimen	36 (70.6%)	34 (50.0%)	27 (75.0%)	0.048	66 (66.7%)	25 (54.3%)	0.329
	At infusion of graft (Day 0 +/- 1d)	9 (17.7%)	26 (38.2%)	7 (19.4%)		25 (25.3%)	15 (32.6%)	
	Other	6 (11.8%)	8 (11.8%)	2 (5.6%)		8 (8.1%)	6 (13.0%)	
Indicate the duration of antifungal prophylaxis used by	Treat until engraftment	11 (22.0%)	17 (25.0%)	7 (19.4%)	0.664	21 (21.2%)	11 (24.4%)	0.651
your center.	Treat until day 75-100	26 (52.0%)	28 (41.2%)	20 (55.6%)		52 (52.5%)	20 (44.4%)	
	Other	13 (26.0%)	23 (33.8%)	9 (25.0%)		26 (26.3%)	14 (31.1%)	
Indicate the primary drug used for systemic antifungal	Fluconazole	42 (84.0%)	53 (77.9%)	29 (80.6%)	0.886	81 (81.8%)	34 (75.6%)	0.6
prophylaxis at your center.	Itraconazole	5 (10.0%)	8 (11.8%)	18 (11.7%)		11 (11.1%)	7 (15.6%)	
	Other	3 (6.0%)	7 (10.3%)	12 (7.8%)		7 (7.1%)	4 (8.9%)	